Drug intelligence / Profile preview

Tavo-111

Development stage: Unknown
Lead developer: Tavotek Biotherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intratumoral

Overview

**Tavo-111** is a bispecific antibody immunomodulator under development for the treatment of neoplasms. It modulates immune responses to target cancer cells, though specific details on its binding targets, mechanism of action, or clinical indications remain limited in available data. Developed as a novel biologic, it represents an early-stage asset in oncology immunotherapy with pending R&D status.[11]

Beyond the preview

Go deeper on Tavo-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tavo-111.

Explore the full profile